Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 60.59 points (-0.3%) at 17,824 as of Friday, Feb. 6, 2015, 4:20 PM ET. The NYSE advances/declines ratio sits at 1,145 issues advancing vs. 1,963 declining with 115 unchanged.

The Consumer Durables industry as a whole closed the day up 0.2% versus the S&P 500, which was down 0.3%. Top gainers within the Consumer Durables industry included Global-Tech Advanced Innovations ( GAI), up 1.8%, Kewaunee Scientific ( KEQU), up 2.7%, EveryWare Global ( EVRY), up 41.9%, Acme United ( ACU), up 2.2% and Nova Lifestyle ( NVFY), up 3.0%.

TheStreet Ratings Group would like to highlight 3 stocks pushing the industry higher today:

Acme United ( ACU) is one of the companies that pushed the Consumer Durables industry higher today. Acme United was up $0.40 (2.2%) to $18.92 on light volume. Throughout the day, 200 shares of Acme United exchanged hands as compared to its average daily volume of 5,600 shares. The stock ranged in a price between $18.60-$18.92 after having opened the day at $18.60 as compared to the previous trading day's close of $18.52.

Acme United Corporation, together with its subsidiaries, supplies cutting, measuring, and first aid products to the school, home, office, hardware, sporting goods, and industrial markets in the United States, Canada, Europe, and Asia. Acme United has a market cap of $61.6 million and is part of the consumer goods sector. Shares are down 6.3% year-to-date as of the close of trading on Thursday. Currently there is 1 analyst who rates Acme United a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates Acme United as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

Highlights from TheStreet Ratings analysis on ACU go as follows:

  • The revenue growth came in higher than the industry average of 8.1%. Since the same quarter one year prior, revenues rose by 35.6%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • The debt-to-equity ratio is somewhat low, currently at 0.78, and is less than that of the industry average, implying that there has been a relatively successful effort in the management of debt levels. To add to this, ACU has a quick ratio of 2.04, which demonstrates the ability of the company to cover short-term liquidity needs.
  • Investors have apparently begun to recognize positive factors similar to those we have mentioned in this report, including earnings growth. This has helped drive up the company's shares by a sharp 30.20% over the past year, a rise that has exceeded that of the S&P 500 Index. Regarding the stock's future course, although almost any stock can fall in a broad market decline, ACU should continue to move higher despite the fact that it has already enjoyed a very nice gain in the past year.
  • ACME UNITED CORP has improved earnings per share by 17.2% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, ACME UNITED CORP increased its bottom line by earning $1.22 versus $1.14 in the prior year. This year, the market expects an improvement in earnings ($1.36 versus $1.22).
  • The net income growth from the same quarter one year ago has exceeded that of the S&P 500 and greatly outperformed compared to the Commercial Services & Supplies industry average. The net income increased by 24.0% when compared to the same quarter one year prior, going from $0.96 million to $1.19 million.

You can view the full analysis from the report here: Acme United Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

At the close, EveryWare Global ( EVRY) was up $0.39 (41.9%) to $1.32 on heavy volume. Throughout the day, 2,250,685 shares of EveryWare Global exchanged hands as compared to its average daily volume of 66,000 shares. The stock ranged in a price between $0.91-$1.75 after having opened the day at $0.91 as compared to the previous trading day's close of $0.93.

EveryWare Global has a market cap of $21.0 million and is part of the consumer goods sector. Shares are up 30.1% year-to-date as of the close of trading on Thursday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Kewaunee Scientific ( KEQU) was another company that pushed the Consumer Durables industry higher today. Kewaunee Scientific was up $0.48 (2.7%) to $18.00 on average volume. Throughout the day, 2,708 shares of Kewaunee Scientific exchanged hands as compared to its average daily volume of 2,200 shares. The stock ranged in a price between $17.75-$18.00 after having opened the day at $17.89 as compared to the previous trading day's close of $17.52.

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture products. The company operates through two segments, Domestic Operations and International Operations. Kewaunee Scientific has a market cap of $47.3 million and is part of the consumer goods sector. Shares are up 1.1% year-to-date as of the close of trading on Thursday. Currently there are no analysts who rate Kewaunee Scientific a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Kewaunee Scientific as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, good cash flow from operations and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

Highlights from TheStreet Ratings analysis on KEQU go as follows:

  • The revenue growth came in higher than the industry average of 0.8%. Since the same quarter one year prior, revenues rose by 15.9%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • KEQU's debt-to-equity ratio is very low at 0.15 and is currently below that of the industry average, implying that there has been very successful management of debt levels. To add to this, KEQU has a quick ratio of 1.77, which demonstrates the ability of the company to cover short-term liquidity needs.
  • KEWAUNEE SCIENTIFIC CORP reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. During the past fiscal year, KEWAUNEE SCIENTIFIC CORP increased its bottom line by earning $1.48 versus $1.17 in the prior year.
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income increased by 65.8% when compared to the same quarter one year prior, rising from $0.73 million to $1.20 million.

You can view the full analysis from the report here: Kewaunee Scientific Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.